197 related articles for article (PubMed ID: 3585412)
1. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer.
Watanabe Y; Iwa T
J Biol Response Mod; 1987 Apr; 6(2):169-80. PubMed ID: 3585412
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy for lung cancer by streptococcal preparation OK-432].
Watanabe Y; Shimizu J; Yoshida Y; Hashizume Y; Yamada T; Iwa T
Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1432-5. PubMed ID: 2586434
[TBL] [Abstract][Full Text] [Related]
3. [Surgery and adjuvant therapy of non-small cell lung cancer].
Watanabe Y; Yamada T; Ichihashi T; Hashizume Y; Iwa T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1534-46. PubMed ID: 3524465
[TBL] [Abstract][Full Text] [Related]
4. [Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy].
Watanabe Y; Sato H; Iida S; Yamada T; Kobayashi H; Kimoto H; Tsunamura Y; Ichihashi T; Shimizu J; Hashizume Y
Gan To Kagaku Ryoho; 1985 Jan; 12(1):21-35. PubMed ID: 2981515
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer.
Sakamoto J; Teramukai S; Watanabe Y; Hayata Y; Okayasu T; Nakazato H; Ohashi Y;
J Immunother; 2001; 24(3):250-6. PubMed ID: 11394503
[TBL] [Abstract][Full Text] [Related]
6. [Immunochemotherapy of resectable lung cancer--a preliminary study on a comparison of the control, levamisole, and OK-432].
Okayasu T; Kashimura Y; Matano J; Kawabata M; Takeoka T; Hashimoto M; Tanabe T
Gan To Kagaku Ryoho; 1982 Sep; 9(9):1646-52. PubMed ID: 6764120
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432.
Watanabe Y; Iwa T
Cancer; 1984 Jan; 53(2):248-53. PubMed ID: 6690008
[TBL] [Abstract][Full Text] [Related]
8. [A randomized controlled study of post-operative adjuvant therapy in non-small cell lung cancer].
Fukushima M; Tsushima T; Ito H; Fukuda Y; Maruyama A; Fujita H; Yagihashi N; Tsuge T; Ishioka T; Kudo T; Kishibe S; Sato T; Machida S; Kogawa R; Takashima K; Koie H; Fujita K
Gan To Kagaku Ryoho; 1996 Feb; 23(3):303-9. PubMed ID: 8712823
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of immunotherapy for lung cancer--present and future].
Watanabe Y; Shimizu J; Oda M; Yoshida M; Watanabe S; Iwa T
Nihon Geka Gakkai Zasshi; 1991 Sep; 92(9):1217-20. PubMed ID: 1944190
[TBL] [Abstract][Full Text] [Related]
10. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
Kimura H; Yamaguchi Y
Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy of gastric cancer].
Kan N; Ohgaki K; Okino T; Nakanishi M; Nio Y; Inoue K; Tobe T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):755-62. PubMed ID: 3291771
[TBL] [Abstract][Full Text] [Related]
12. [Transfer factor immunochemotherapy for primary lung cancer--evaluation of histologic types].
Fujisawa T; Yamaguchi Y
Gan No Rinsho; 1983 Oct; 29(12):1409-16. PubMed ID: 6315989
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer].
Kikkawa N; Sasai H; Kawahara T
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2163-9. PubMed ID: 6486832
[TBL] [Abstract][Full Text] [Related]
14. [Relation between prognosis and the Su-PS skin reaction in patients with non-resected primary lung cancer receiving OK-432].
Nakarai I; Rikitake H; Koga T; Hayashi A; Harada Y; Takamoto M; Ishibashi T; Shinoda A; Sagawa K
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3050-7. PubMed ID: 2823723
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy, with OK-432 for cases of nasopharyngeal carcinoma].
Tsukuda M; Tamamushi N; Mochimatsu I; Mitarai K; Kaneko M; Sawaki S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):53-9. PubMed ID: 3942399
[TBL] [Abstract][Full Text] [Related]
16. [Randomized controlled study of OK-432 in the treatment of cancerous pleurisy].
Urata A; Nishimura M; Ota K
Gan To Kagaku Ryoho; 1983 Jun; 10(6):1497-503. PubMed ID: 6409006
[TBL] [Abstract][Full Text] [Related]
17. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer.
Kimura T; Suzuki K; Motai H; Miyamoto N; Tsuge I; Ito Y; Baba S
Acta Otolaryngol Suppl; 1996; 525():135-41. PubMed ID: 8908288
[TBL] [Abstract][Full Text] [Related]
18. Immuno-chemotherapy of malignant lymphoma using OK-432, a streptococcal agent.
Kimura I; Ohnoshi T; Nakata Y; Takasugi K; Fujii M; Hayashi K; Kataoka M; Sato M; Nishihara R
Acta Med Okayama; 1979 Dec; 33(6):471-8. PubMed ID: 94239
[TBL] [Abstract][Full Text] [Related]
19. [A controlled study of surgical adjuvant chemoimmunotherapy with FT-207 and OK-432 for advanced stomach cancer: the fourth study].
Yamamura Y; Yasue M; Nakazato H; Ota K
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):541-8. PubMed ID: 3923941
[TBL] [Abstract][Full Text] [Related]
20. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group.
J Thorac Cardiovasc Surg; 1985 Jun; 89(6):842-7. PubMed ID: 2860271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
